VM
VM4.F Vanda Pharmaceuticals Inc
- Market cap
- EUR 212M
- P/E
- -
- P/B
- 1.21x
- ROE
- -89.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is VM4.F undervalued?
Graham numberThe Graham number of Vanda Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vanda Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Vanda Pharmaceuticals Inc yet.
Vanda Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; …
Full company profileVanda Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vanda Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 146M | 165M | 193M | 227M | 248M | 269M | 254M | 193M | 199M | 216M | 229M |
| Gross Profit | 121M | 147M | 173M | 203M | 225M | 243M | 230M | 178M | 187M | 203M | 215M |
| Operating Income | -18.6M | -16.9M | 21.7M | 22.8M | 27.2M | 42.2M | 6.33M | -14.0M | -40.7M | -151M | -183M |
| EBITDA | - | -13.9M | 24.7M | 25.7M | 30.1M | 45.0M | 7.85M | -9.62M | -30.9M | -139M | -169M |
| Net Income | -18.0M | -15.6M | 25.2M | 116M | 23.3M | 33.2M | 6.28M | 2.51M | -18.9M | -220M | -178M |
| EPS | - | -0.35 | 0.48 | 2.16 | 0.43 | 0.59 | 0.11 | 0.04 | -0.32 | -3.73 | -2.95 |
| Balance Sheet | |||||||||||
| Total Assets | 210M | 205M | 332M | 484M | 533M | 594M | 634M | 648M | 656M | 489M | 382M |
| Total Liabilities | 79.0M | 74.0M | 56.7M | 72.8M | 80.2M | 88.9M | 107M | 104M | 118M | 162M | 182M |
| Shareholders' Equity | 131M | 131M | 275M | 411M | 453M | 505M | 527M | 545M | 539M | 327M | 200M |
| Cash & Short-term Investments | 40.4M | 33.6M | 61.0M | 45.1M | 61.0M | 52.1M | 135M | 136M | 102M | 84.9M | 61.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.10M | -1.98M | 30.0M | 45.9M | 51.8M | 64.2M | 32.0M | 25.9M | -15.8M | -109M | -146M |
| Capital Expenditure | 1.41M | 1.66M | 368K | 1.02M | 1.80M | 552K | 679K | 393K | 490K | 998K | 14.3M |
| Free Cash Flow | - | -3.65M | 4.62M | 44.9M | 50.0M | 63.7M | 31.3M | 25.6M | -16.2M | -110M | -161M |
| Ratios | |||||||||||
| ROE | -13.7% | -11.8% | 9.2% | 28.1% | 5.1% | 6.6% | 1.2% | 0.5% | -3.5% | -67.4% | -89.2% |
| ROA | -8.6% | -7.6% | 7.6% | 23.9% | 4.4% | 5.6% | 1.0% | 0.4% | -2.9% | -45.1% | -46.6% |
| Net Profit Margin | -12.3% | -9.4% | 13.1% | 50.9% | 9.4% | 12.3% | 2.5% | 1.3% | -9.5% | -102.0% | -77.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Vanda Pharmaceuticals Inc dividends
Vanda Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Vanda Pharmaceuticals Inc
- Insiders 6.79%
- Institutions 87.48%
- Public & others 5.73%
- Shares outstanding 60.5M
- Free float 46.8M
Vanda Pharmaceuticals Inc company profile
- Company name
- Vanda Pharmaceuticals Inc
- Ticker
- VM4.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 533
- Fiscal year end
- December
- Address
- 2200 Pennsylvania Avenue NW, Washington, DC, United States, 20037
- Phone
- 202 734 3400
- Website
- vandapharma.com
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Vanda Pharmaceuticals Inc management
7- Dr. Mihael H. Polymeropoulos M.D.Founder, President, CEO & Chairman of The Board · born 1960
- Mr. Kevin Patrick MoranSenior VP, CFO & Treasurer · born 1984
- Mr. Joakim WijkstromSenior VP & Chief Marketing Officer · born 1966
- Mr. Gunther BirznieksSenior Vice President of Business Development · born 1969
- Mr. Daniel Patrick McGuireSenior VP, General Counsel & Secretary
- Mr. Scott L. HowellChief People Officer · born 1975
- Mr. Christos Polymeropoulos M.D.Senior Vice President & Medical Director